2,348
Views
39
CrossRef citations to date
0
Altmetric
Research Article

EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer

, , , , , & show all
Pages 2936-2945 | Received 07 Oct 2015, Accepted 28 Nov 2015, Published online: 07 Jan 2016

References

  • Beh CW, Seow WY, Wang Y, et al. (2008). Efficient delivery of Bcl-2-targeted siRNA using cationic polymer nanoparticles: downregulating mRNA expression level and sensitizing cancer cells to anticancer drug. Biomacromolecules 10:41–8
  • Beija M, Salvayre R, Lauth-de Viguerie N, et al. (2012). Colloidal systems for drug delivery: from design to therapy. Trends Biotechnol 30:485–96
  • Brand TM, Iida M, Luthar N, et al. (2013). Nuclear EGFR as a molecular target in cancer. Radiother Oncol 108:370–7
  • Brannon-Peppas L, Blanchette JO. (2012). Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev 64:206–12
  • Chougule A, Prabhash K, Noronha V, et al. (2013). Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS One 8:e76164
  • Davis ME, Zuckerman JE, Choi CHJ, et al. (2010). Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464:1067–70
  • Du J, Sun Y, Shi QS, et al. (2012). Biodegradable nanoparticles of mPEG-PLGA-PLL triblock copolymers as novel non-viral vectors for improving siRNA delivery and gene silencing. Int J Mol Sci 13:516–33
  • Farokhzad OC, Cheng J, Teply BA, et al. (2006). Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. Proc Natl Acad Sci USA 103:6315–20
  • Heo MB, Lim YT. (2014). Programmed nanoparticles for combined immunomodulation, antigen presentation and tracking of immunotherapeutic cells. Biomaterials 35:590–600
  • Jain RK, Stylianopoulos T. (2010). Delivering nanomedicine to solid tumors. Nat Rev Clin Oncol 7:653–64
  • Koty PP, Zhang H, Levitt ML. (1999). Antisense bcl-2 treatment increases programmed cell death in non-small cell lung cancer cell lines. Lung Cancer 23:115–27
  • Li HY, Hu J, Zhao S, et al. (2012). Comparative study of the effect of baicalin and its natural analogs on neurons with oxygen and glucose deprivation involving innate immune reaction of TLR2/TNFα. J Biomed Biotechnol 2012:Article ID 267890
  • Liu P, Yu H, Sun Y, et al. (2012). A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery. Biomaterials 33:4403–12
  • Lwin Z, Riess JW, Gandara D. (2013). The continuing role of chemotherapy for advanced non-small cell lung cancer in the targeted therapy era. J Thorac Dis 5:S556–64
  • Molina JR, Yang P, Cassivi SD, et al. (2008). Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clinic Proc 83:584–94
  • Rathos MJ, Khanwalkar H, Joshi K, et al. (2013). Potentiation of in vitro and in vivo antitumor efficacy of doxorubicin by cyclin-dependent kinase inhibitor P276-00 in human non-small cell lung cancer cells. BMC Cancer 13:29
  • Sartorius UA, Krammer PH. (2002). Upregulation of bcl-2 is involved in the mediation of chemotherapy resistance in human small cell lung cancer cell lines. Int J Cancer 97:584–92
  • Sheng Q, Liu J. (2011). The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 104:1241–5
  • Siegel R, Naishadham D, Jemal A. (2012). Cancer statistics. Cancer J Clin 62:10–29
  • Siegel R, Naishadham D, Jemal A. (2013). Cancer statistics, 2013. Cancer J Clin 63:11–30
  • Singhal SS, Wickramarachchi D, Singhal J, et al. (2006). Determinants of differential doxorubicin sensitivity between SCLC and NSCLC. FEBS Lett 580:2258–64
  • Sridhar SS, Seymour L, Shepherd FA. (2003). Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer. Lancet Oncol 4:397–406
  • Stigliano C, Aryal S, de Tullio MD, et al. (2014). siRNA-chitosan complexes in poly(lactic-co-glycolic acid) nanoparticles for the silencing of aquaporin-1 in cancer cells. Mol Pharm 10:3186–94
  • Su WP, Cheng FY, Shieh DB, et al. (2012). PLGA nanoparticles codeliver paclitaxel and Stat3 siRNA to overcome cellular resistance in lung cancer cells. Int J Nanomedicine 7:4269–83
  • Tseng CL, Wang TW, Dong GC, et al. (2007). Development of gelatin nanoparticles with biotinylated EGF conjugation for lung cancer targeting. Biomaterials 28:3996–4005
  • Wang JQ, Du ZW, Gao XF, et al. (2013a). [The effect of Bcl-2 gene silencing on the sensitivity of cell line A549 to chemotherapeutic drugs]. Zhonghua Jie He Hu Xi Za Zhi 36:191–7
  • Wang Y, Liu P, Qiu L, et al. (2013b). Toxicity and therapy of cisplatin-loaded EGF modified mPEG-PLGA-PLL nanoparticles for SKOV3 cancer in mice. Biomaterials 34:4068–77
  • Wu DW, Wu TC, Wu JY, et al. (2013). Phosphorylation of paxillin confers cisplatin resistance in non-small cell lung cancer via activating ERK-mediated Bcl-2 expression. Oncogene 33:4385–95
  • Yang J, Liu X, Bhalla K, et al. (1997). Prevention of apoptosis by Bcl-2: release of cytochrome c from mitochondria blocked. Science 275:1129–32
  • Yin P, Wang Y, Qiu YY, et al. (2012). Bufalin-loaded mPEG-PLGA-PLL-cRGD nanoparticles: preparation, cellular uptake, tissue distribution, and anticancer activity. Int J Nanomedicine 7:3961–9
  • Zarogoulidis K, Zarogoulidis P, Darwiche K, et al. (2013). Treatment of non-small cell lung cancer (NSCLC). J. Thorac Dis 5:S389–96
  • Zhao P, Dai M, Chen W, et al. (2010). Cancer trends in China. Jpn J Clin Oncol 40:281–5
  • Ziegler A, Luedke GH, Fabbro D, et al. (1997). Induction of apoptosis in small-cell lung cancer cells by an antisense oligodeoxynucleotide targeting the Bcl-2 coding sequence. J Natl Cancer Inst 89:1027–36

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.